Lorenz Thurner

Lorenz Thurner

Auto-generated profile, based on publicly available information

Lorenz Thurner

Internal Medicine I, School of Medicine, Saarland University, 66421 Homburg, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LTLorenz Thurner
Lorenz Thurner
CKChristoph Kessel
Christoph Kessel
NFNatalie Fadle
Natalie Fadle
EREvi Regitz
Evi Regitz
FSFranziska Seidel
Franziska Seidel
KKKarin Klingel
Karin Klingel
Myocarditis associated with messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) predominantly affects male adolescents and young male adults (14 to <30 years of age) and typically occurs after receipt of the second vaccine dose.1,2 In adults with critical coronavirus disease 2019 (Covid-19) and in cases of multisystem inflammatory syndrome in children (MIS-C), we recently discovered neutralizing autoantibodies targeting the endogenous interleukin-1 receptor antagonist (IL-1RA), which inhibits interleukin-1 signaling and inflammation.3,4

1 May 2013 in Journal of Autoimmunity
Verified
Journal Article
Closed access
LTLorenz Thurner
Lorenz Thurner
KPKlaus-Dieter Preuss
Klaus-Dieter Preuss
NFNatalie Fadle
Natalie Fadle
EREvi Regitz
Evi Regitz
PKPhilipp Klemm
Philipp Klemm
MPMichael Pfreundschuh
Michael Pfreundschuh

18 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
LTLorenz Thurner
Lorenz Thurner
SHSylvia Hartmann
Sylvia Hartmann
NFNatalie Fadle
Natalie Fadle
EREvi Regitz
Evi Regitz
MKMaria Kemele
Maria Kemele
MPMichael Pfreundschuh
Michael Pfreundschuh
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma of B-cell origin with frequent expression of functional B-cell receptors (BCRs). Here we report that expression cloning followed by antigen screening identifies DNA-directed RNA polymerase beta’ (RpoC) fromMoraxella catarrhalisas frequent antigen of BCRs of IgD+LP cells. Patients show predominance of HLA-DRB1*04/07 and the IgVH genes encode extraordinarily long CDR3s. High-titer, light-chain-restricted anti-RpoC IgG1/κ-type serum-antibodies are additionally found in these patients. RpoC and MID/hag, a superantigen co-expressed byMoraxella catarrhalisthat is known to activate IgD+B cells by binding to the Fc domain of IgD, have additive activation effects on the BCR, the NF-κB pathway and the proliferation of IgD+DEV cells expressing RpoC-specific BCRs. This suggests an additive antigenic and superantigenic stimulation of B cells with RpoC-specific IgD+BCRs under conditions of a permissive MHC-II haplotype as a model of NLPHL lymphomagenesis, implying future treatment strategies.

19 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MBMoritz Bewarder
Moritz Bewarder
SSStephan Stilgenbauer
Stephan Stilgenbauer
LTLorenz Thurner
Lorenz Thurner
DKDominic Kaddu-Mulindwa
Dominic Kaddu-Mulindwa
After impressive developments in recent years with the rise of new targeted agents, chemoimmunotherapy (CIT) only plays a minor role in the treatment of patients with chronic lymphocytic leukemia (CLL). Inhibitors of the Bruton tyrosine kinase (BTK), such as ibrutinib or more recently acalabrutinib, are highly effective, even in poor-risk or chemo-refractory patients. Venetoclax, an inhibitor of the anti-apoptotic BCL2 protein and, to a lesser extent, phosphoinositide-3 kinase (PI3K) delta inhibitors, add to the armamentarium of targeted agents for the treatment of CLL. Furthermore, anti-CD20 monoclonal antibodies are used very successfully either alone or in combination with BTK, BCL2 or PI3K inhibitors. Despite these advances, there is still an ongoing pursuit for new therapeutic approaches in the treatment of CLL. An even bigger challenge poses the determination of the optimal combination and sequence of those drugs. Here, we give an overview of current treatment options in CLL, weighing the advantages and disadvantages of each approach in the light of different clinical settings.

31 July 2025 in Blood Advances
Verified
Journal Article
Open access
ESEvgenii Shumilov
Evgenii Shumilov
JSJulia Katharina Scholz
Julia Katharina Scholz
MSMaximilian Seib
Maximilian Seib
PMPaolo Mazzeo
Paolo Mazzeo
RWRebecca Wurm-Kuczera
Rebecca Wurm-Kuczera
GLGeorg Lenz
Georg Lenz
Patients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in ∼35% of these cases. Hypothesizing overlapping LBCL-intrinsic resistance mechanisms as well as common poor prognosis predictors to CAR-T and BsAb therapy, we conducted a multicenter retrospective analysis including 92 patients with relapsed/refractory (R/R) LBCL treated with BsAbs after CAR-T failure. Overall response rate (ORR) was 43%, with a progression-free survival (PFS) of 2.8 months. Patients receiving BsAbs during early relapse (≤3 months) achieved a significantly worse outcome (ORR, 29%; PFS, 2.2 months) compared with patients with an intermediate (4-6 months; ORR, 54%; PFS, 3.7 months) or a late relapse (>6 months; ORR, 60%; PFS, 10.5 months). The benefit of later relapse was particularly notable in patients receiving BsAbs as first salvage therapy compared with those receiving a BsAb in subsequent lines (PFS not reached vs 2.7 months; overall survival not reached vs 9.1 months, respectively). In addition to early R/R state before BsAbs, elevated lactate dehydrogenase and higher International Prognostic Index score were significant predictors of poor outcomes to BsAb in multivariate Cox regression analyses. The finding that patients with early relapse after CAR-T respond particularly poorly to BsAb highlights the necessity for alternative treatment options in this high-risk patient cohort.

10 December 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
LTLorenz Thurner
Lorenz Thurner
MZMarina Zaks
Marina Zaks
KPKlaus-Dieter Preuss
Klaus-Dieter Preuss
NFNatalie Fadle
Natalie Fadle
EREvi Regitz
Evi Regitz
GAGunter Assmann
Gunter Assmann
Introduction: Psoriatic arthritis (PsA) is a distinctive inflammatory arthritis which may typically develop in a subgroup of individuals suffering from psoriasis. We recently described progranulin autoantibodies (PGRN-Abs) in the sera of patients with different autoimmune diseases including seronegative polyarthritis. In the present study we investigated the occurrence of PGRN-Abs in PsA. Methods: PGRN-Abs were determined in 260 patients with PsA, 100 patients with psoriasis without arthritic manifestations (PsC) and 97 healthy controls using a recently described ELISA. PGRN plasma levels were determined from subgroups by a commercially available ELISA-kit. Possible functional effects of PGRN-antibodies were analysed in vitro by tumour necrosis factor (TNF)-α mediated cytotoxicity assays using WEHI-S and HT1080 cells. Results: PGRN-Abs were detected with relevant titres in 50/260 (19.23%) patients with PsA, but in 0/100 patients with psoriasis without arthritic manifestations (P = 0.0001). All PGRN-Abs belonged to immunoglobulin G (IgG). PGRN-Abs were significantly more frequent in PsA patients with enthesitis or dactylitis. PGRN-Abs were also more frequent in PsA patients receiving treatment with TNF-α-blockers than in patients treated without TNF-α-blockers (20.8% versus 17.4%; P = 0.016). PGRN plasma levels were significantly lower in PGRN-Ab-positive patients with PsA than in healthy controls and patients with psoriasis without arthritic manifestations (P < 0.001), indicating a neutralizing effect of PGRN-Abs. Moreover cytotoxicity assays comparing PGRN-antibody positive with negative sera from matched patients with PsA, clearly showed a proinflammatory effect of PGRN antibodies. Conclusion: Neutralizing PGRN-Abs occur with relevant titres in a subgroup of patients with PsA, but not in patients without arthritic manifestations (PsC). PGRN-Ab-positive patients had more frequent enthesitis or dactylitis. TNF-α-induced cytotoxicity assays demonstrated that the protective effects of progranulin were inhibited by serum containing PGRN-Abs. This suggests that PGRN-Ab might not only be useful as a diagnostic and prognostic marker, but may provide a proinflammatory environment in a subgroup of patients with PsA.